What problem does this paper attempt to address?

This paper aims to solve the problem of ubiquitin - proteasome system (UPS) dysfunction in neurodegenerative diseases related to abnormal tau protein aggregation. Specifically, the research focuses on: 1. **Whether abnormal tau protein aggregation will affect the function of 26S proteasome**: By using a mouse model (rTg4510) expressing pathological tau mutation (P301L), the study found that with age and the progress of tau protein pathological state, the peptidase activity of 26S proteasome decreased significantly, leading to the accumulation of ubiquitinated proteins. 2. **The relationship between UPS dysfunction and tau protein pathology**: The research shows that in the tau proteinopathy mouse model, with the abnormal aggregation of tau protein, UPS function is gradually impaired, manifested as the decrease of peptidase activity of 26S proteasome, the weakening of ATP hydrolysis ability and the increase of ubiquitinated protein accumulation. 3. **Whether activating the cAMP - PKA signaling pathway can improve UPS function and alleviate the symptoms of tau proteinopathy**: The study found that by increasing the cAMP level in the brain with drugs (such as rolipram) and activating the PKA signaling pathway, the phosphorylation modification of proteasome can be enhanced, thereby increasing its activity, reducing the abnormal aggregation of tau protein, and improving cognitive function. ### Specific problem description The core problem that this paper attempts to solve is: **In the process of tau proteinopathy, whether the function of 26S proteasome will be damaged, and whether activating the cAMP - PKA signaling pathway can prevent or reverse this damage, thereby improving the symptoms of neurodegenerative diseases**. ### Main conclusions 1. **Abnormal tau protein aggregation does lead to 26S proteasome dysfunction**, manifested as the decrease of peptidase activity and the accumulation of ubiquitinated proteins. 2. **Activating the cAMP - PKA signaling pathway can enhance the phosphorylation modification of proteasome**, thereby increasing its activity, reducing the abnormal aggregation of tau protein, and improving cognitive function. 3. **These findings provide a theoretical basis for the development of new treatment strategies**, especially for the treatment of tau proteinopathy and other related neurodegenerative diseases. ### Related formulas The biochemical reactions and molecular mechanisms involved in the discussion can be represented by the following formulas: - The accumulation of cAMP can be achieved by inhibiting phosphodiesterase (PDE4): \[ \text{PDE4} \rightarrow \text{cAMP} \] - Phosphorylation modification of proteasome subunits after PKA activation: \[ \text{PKA}+\text{Proteasome Subunits} \rightarrow \text{Phosphorylated Proteasome Subunits} \] These mechanisms work together to ultimately improve the degradation ability of proteasome and reduce the abnormal aggregation of tau protein.

Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling

Cilostazol, a phosphodiesterase 3 inhibitor, activates proteasome-mediated proteolysis and attenuates tauopathy and cognitive decline

Tau Protein Antagonizes Cell Apoptosis Through Akt Pathway

Tau inhibits PKA by nuclear proteasome-dependent PKAR2α elevation with suppressed CREB/GluA1 phosphorylation

Broad activation of the Parkin pathway induces synaptic mitochondrial deficits in early tauopathy

Selective degradation of hyperphosphorylated tau by proteolysis-targeting chimeras ameliorates cognitive function in Alzheimer's disease model mice

Mitochondrial bioenergetics stimulates autophagy for pathological MAPT/Tau clearance in tauopathy neurons

Broad activation of the PRKN pathway triggers synaptic failure by disrupting synaptic mitochondrial supply in early tauopathy

Regulating the Ubiquitin/Proteasome Pathway Via cAMP-signaling: Neuroprotective Potential

Phenotypic Discovery of Neuroprotective Agents by Regulation of Tau Proteostasis via Stress‐Responsive Activation of PERK Signaling

Reduction of advanced tau‐mediated memory deficits by the MAP kinase p38γ

Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ

Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer's disease mouse model

β-Amyloid impairs Proteasome structure and function. Proteasome activation mitigates amyloid induced toxicity and cognitive deficits

Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy

Tau activation of microglial cGAS–IFN reduces MEF2C-mediated cognitive resilience

Tau accumulation is cleared by the induced expression of VCP via autophagy

Akt activation ameliorates deficits in hippocampal-dependent memory and activity-dependent synaptic protein synthesis in an Alzheimer’s disease mouse model

5-HT4 receptor agonists treatment reduces tau pathology and behavioral deficit in the PS19 mouse model of tauopathy

Pharmacological GCase Activity Enhancement Inhibits Tau Accumulation

Microglial lipid droplet accumulation in tauopathy brain is regulated by neuronal AMPK